NEPHRIX Biosolutions is a privately held preclinical Contract Research Organisation headquartered at 516, rue Pierre et Marie Curie, 31670 Labège, France, within the greater Toulouse biotechnology cluster. The company was established in 2021 with a singular scientific focus on nephrology and renal fibrosis, positioning itself as a specialist CRO for pharmaceutical, biotechnology, and academic clients developing therapeutics for kidney diseases, chronic kidney disease (CKD), acute kidney injury (AKI), and fibrotic conditions.

The company’s scientific model is built on the conviction that renal drug development requires indication-specific expertise, purpose-developed models, and translational rigour beyond what is typically available at generalist preclinical CROs. NEPHRIX offers in vitro cell-based assays using human primary cells, a range of validated surgical and pharmacological in vivo rodent models, dedicated histology and digital pathology capabilities, and biomarker analysis services — all scoped exclusively within the renal and fibrotic disease space. Clients include pharmaceutical companies, biotechnology firms, and academic partners, accessible through Scientist.com and Science Exchange in addition to direct engagement.

The company’s ethical and 3Rs (Replacement, Reduction, Refinement) commitment is explicitly stated, and its in vitro service portfolio reflects a practical application of these principles by providing human primary cell-based assays as earlier-stage alternatives to animal models where scientifically appropriate.

Key Products and Services

In Vitro Assays

• Fibrosis Assay — cell-based fibrosis assessment using human primary fibroblasts from renal, lung, cardiac, and skin origins; suitable for compound screening and efficacy evaluation against fibrotic endpoints including collagen deposition, myofibroblast activation, and pro-fibrotic gene expression
• DuoXProx™ Renal Co-Culture Model — proprietary in vitro renal co-culture system incorporating proximal tubular epithelial cells and interstitial fibroblasts, enabling more physiologically representative assessment of tubulo-interstitial crosstalk in fibrosis and nephrotoxicity studies than mono-culture formats
• Inflammation Assay — in vitro inflammation model using human primary cells to assess pro-inflammatory cytokine release, immune cell activation, and anti-inflammatory compound activity in renal pathology-relevant contexts
• Senescence Assay — in vitro senescence-associated β-galactosidase (SA-β-Gal) assay platform using human primary cells from multiple tissue origins, relevant to CKD and age-related renal pathology programmes

In Vivo Rodent Models

• Ischemia Reperfusion Injury (IRI) Model — surgical induction of acute kidney injury via renal ischaemia and reperfusion in mouse and rat; used for AKI mechanistic studies and therapeutic intervention assessment
• Unilateral Ureteral Obstruction (UUO) Model — surgical UUO in mouse and rat to induce progressive tubulointerstitial fibrosis and CKD; a well-validated model for renal fibrosis drug efficacy evaluation
• Streptozotocin (STZ) Diabetic Nephropathy Model — pharmacological induction of type 1 diabetes in rat and mouse via STZ, generating a model of diabetic nephropathy with pathological features including glomerular hypertrophy, proteinuria, and progressive fibrosis
• IgA Nephropathy (IgAN) Model — rodent model of IgA nephropathy/glomerulonephritis for the evaluation of therapeutics targeting immune-mediated renal injury
• Adenine Diet Model — adenine-induced CKD model producing tubulointerstitial nephritis and progressive renal fibrosis; a robust pharmacological model for chronic kidney disease drug evaluation
• Nephrotoxicity Model — cisplatin-induced AKI model for assessment of nephroprotective agents and evaluation of drug candidate renal safety liabilities

Histology Services

• Tissue processing, sectioning, and standard histological staining (H&E, Masson’s trichrome, PAS, Sirius Red) for renal tissue characterisation
• Quantitative digital pathology — image analysis-based quantification of fibrosis area, glomerular morphology, tubular injury scoring, and other structural endpoints
• Immunohistochemistry (IHC) for protein expression localisation within kidney tissue sections

Biomarker Services

• Bioanalysis platform supporting assessment of therapeutic efficacy, safety, and mechanism of action, encompassing plasma, urine, and tissue biomarker quantification
• Renal injury and function biomarkers including creatinine, urea, KIM-1, NGAL, cystatin C, albumin, and urinary protein analysis
• Cytokine and fibrosis marker panels supporting mechanistic and pharmacodynamic readout generation

NEPHRIX Biosolutions occupies a tightly defined niche as a kidney disease-exclusive preclinical CRO — a level of indication specificity that is uncommon in the preclinical services market and that addresses a genuine unmet need for sponsors developing renal therapeutics. Chronic kidney disease, AKI, IgA nephropathy, and diabetic nephropathy represent a substantial and growing drug development opportunity, driven by a combination of high global disease burden, historically poor translational success rates from conventional preclinical models, and a recent wave of mechanistically novel drug candidates in the renal space including SGLT2 inhibitors, endothelin receptor antagonists, and complement pathway inhibitors. NEPHRIX’s exclusive focus on nephrology means that its model portfolio, scientific team, and histopathological infrastructure are all oriented around the specific endpoints, biomarkers, and pathological features relevant to renal drug development — a depth of domain specificity that generalist CROs offering nephrology as one of many therapeutic areas cannot replicate. The DuoXProx™ co-culture model represents a proprietary scientific asset that may differentiate NEPHRIX in early screening and mechanistic study applications. As a company established in 2021, NEPHRIX remains early-stage, but its Toulouse location within a strong French biotech ecosystem, Scientist.com and Science Exchange marketplace presence, and published peer-reviewed scientific output provide a credibility foundation appropriate for engagement with pharmaceutical and biotech sponsors.